A Phase 2 interventional study of bempedoic acid 180mg and placebo in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-03.
Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 16th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 2, and was the 13th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one is the 12th largest by enrollment, is one of 4 that started in 2017, is one of 9 in phase 2, and was the 13th registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9 inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL cholesterol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
Drug: bempedoic acid 180mg · Drug: evolocumab
Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
Other: placebo · Drug: evolocumab
Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
Also known as: ETC-1002
Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy
Monthly PCSK9i (evolocumab) background therapy
Also known as: Repatha
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Month 2
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the average of the last two non-missing values within Month -1 (Screening Visit 4) and Day 1 (Treatment Visit 1) values (including unscheduled assessments). If only one value was available, then that single value was used at Baseline. Percent change from Baseline was analyzed using analysis of covariance (ANCOVA), with treatment group as a factor and Baseline as a covariate. Missing data were imputed using last observation carried forward (LOCF) (only post-Baseline values were carried forward).
Time frame: Baseline; Month 2
Percent Change From Baseline in LDL-C at Month 1
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the average of the last two non-missing values within Month -1 (Screening Visit 4) and Day 1 (Treatment Visit 1) values (including unscheduled assessments). If only one value was available, then that single value was used at Baseline. Percent change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis.
Time frame: Baseline; Month 1
Absolute Change From Baseline in LDL-C at Month 1 and Month 2
Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the average of the Screening Visit 4 and the Day 1 value. If only 1 value is available, then that single value is used as Baseline. Change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis at Month 1. Missing Month 2 data were handled by LOCF.
Time frame: Baseline; Month 1 and Month 2
Percent Change From Baseline in Lipid Profile Parameters at Month 1 and Month 2
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline apolipoprotein B (apoB) is defined as the Day 1 value. Baseline total cholesterol (TC) and non-high-density lipoprotein cholesterol (non-HDL-C) are defined as the average of the Month -1 (Screening Visit 4) and the Day 1 (Treatment Visit 1) values. If a missing value presented at Month -1 or Day 1, then the last non-missing value prior to the first dose of double-blind study medication (including unscheduled assessments) within Month -1 and Day 1 was used to compute the Baseline measurements. Percent change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis at Month 1. Missing Month 2 data were handled by LOCF.
Time frame: Baseline; Month 1 and Month 2
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Month 1 and Month 2
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the Day 1 value. Percent change from Baseline was analyzed using a non-parametric approach. Missing Month 2 data were handled by LOCF. Observed data were used for analysis at Month 1.
Time frame: Baseline; Month 1 and Month 2
Number of Participants With Any Treatment-emergent Adverse Event (AE) and Treatment-emergent Serious Adverse Event (SAE)
Treatment-emergent AEs (TEAEs) and SAEs (TESAEs) were reported and defined as any AE that began or worsened after the first dose of investigational medicinal product.
Time frame: up to Month 2 (until 30 days after last dose)
Number of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3x the Upper Limit of Normal (ULN) at Month 1 and Month 2
The number of participants with ALT or AST \>3x ULN was measured.
Time frame: Month 1 and Month 2
170 participants were screened; out of 170, 59 participants were randomized. One participant never received study medication and withdrew from the study due to the Sponsor's decision.
| Milestone | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab |
|---|---|---|
| Started | 31 | 28 |
| Completed | 29 | 28 |
| Not completed | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Participant left state | 1 | 0 |
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the average of the last two non-missing values within Month -1 (Screening Visit 4) and Day 1 (Treatment Visit 1) values (including unscheduled assessments). If only one value was available, then that single value was used at Baseline. Percent change from Baseline was analyzed using analysis of covariance (ANCOVA), with treatment group as a factor and Baseline as a covariate. Missing data were imputed using last observation carried forward (LOCF) (only post-Baseline values were carried forward).
| percent change | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab |
|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Month 2 | 2.783 ± 3.412 | -27.478 ± 4.310 |
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the average of the last two non-missing values within Month -1 (Screening Visit 4) and Day 1 (Treatment Visit 1) values (including unscheduled assessments). If only one value was available, then that single value was used at Baseline. Percent change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis.
| percent change | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab |
|---|---|---|
| Percent Change From Baseline in LDL-C at Month 1 | 3.172 ± 2.700 | -32.712 ± 4.385 |
Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the average of the Screening Visit 4 and the Day 1 value. If only 1 value is available, then that single value is used as Baseline. Change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis at Month 1. Missing Month 2 data were handled by LOCF.
| milligrams per deciliter (mg/dL) | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab |
|---|---|---|
| Month 1 | 1.75 ± 3.118 | -36.51 ± 46.41 |
| Month 2 | -0.02 ± 3.386 | -29.92 ± 4.461 |
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline apolipoprotein B (apoB) is defined as the Day 1 value. Baseline total cholesterol (TC) and non-high-density lipoprotein cholesterol (non-HDL-C) are defined as the average of the Month -1 (Screening Visit 4) and the Day 1 (Treatment Visit 1) values. If a missing value presented at Month -1 or Day 1, then the last non-missing value prior to the first dose of double-blind study medication (including unscheduled assessments) within Month -1 and Day 1 was used to compute the Baseline measurements. Percent change from Baseline was analyzed using ANCOVA, with treatment group as a factor and Baseline as a covariate. Observed data were used for analysis at Month 1. Missing Month 2 data were handled by LOCF.
| percent change | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab |
|---|---|---|
| apo-B at Month 1 | 0.547 ± 2.948 | -26.484 ± 4.175 |
| non-HDL-C at Month 1 | 2.077 ± 2.378 | -29.563 ± 4.031 |
| TC at Month 1 | 1.170 ± 1.877 | -20.770 ± 3.025 |
| apo-B at Month 2 | 2.706 ± 2.182 | -21.763 ± 3.736 |
| non-HDL-C at Month 2 | 1.285 ± 2.783 | -22.960 ± 3.951 |
| TC at Month 2 | 0.557 ± 2.009 | -16.963 ± 3.228 |
Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the Day 1 value. Percent change from Baseline was analyzed using a non-parametric approach. Missing Month 2 data were handled by LOCF. Observed data were used for analysis at Month 1.
| percent change | Placebo + Evolocumab | Bempedoic Acid + Evolocumab |
|---|---|---|
| hs-CRP at Month 1 | 10.658 (-36.488 to 66.374) | -23.349 (-57.857 to 5.128) |
| hs-CRP at Month 2 | -1.623 (-39.445 to 26.531) | -34.444 (-57.599 to -7.083) |
Treatment-emergent AEs (TEAEs) and SAEs (TESAEs) were reported and defined as any AE that began or worsened after the first dose of investigational medicinal product.
| Participants | Placebo + Evolocumab | Bempedoic Acid + Evolocumab |
|---|---|---|
| Any TEAE | 7 | 9 |
| TEAEs related to IMP | 1 | 1 |
| TEAEs related to evolocumab | 1 | 0 |
| TESAEs | 0 | 1 |
| TESAEs related to IMP | 0 | 0 |
| TESAEs related to evolocumab | 0 | 0 |
| Deaths | 0 | 0 |
| Discontinuation of IMP due to TEAE | 0 | 0 |
| Mild TEAEs | 5 | 4 |
| Moderate TEAEs | 2 | 4 |
| Severe TEAEs | 0 | 1 |
The number of participants with ALT or AST \>3x ULN was measured.
| Participants | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab |
|---|---|---|
| ALT, Month 1 | 0 | 0 |
| ALT, Month 2 | 0 | 0 |
| AST, Month 1 | 0 | 0 |
| AST, Month 2 | 0 | 0 |
Collected over up to Month 2 (until 30 days after last dose). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Plus Evolocumab | 0/30 (0%) | 0/30 (0%) | 7/30 (23.3%) |
| Bempedoic Acid Plus Evolocumab | 0/28 (0%) | 1/28 (3.6%) | 8/28 (28.6%) |
| Event | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab |
|---|---|---|
| InfluenzaInfections and infestations | 0/30 | 1/28 |
| Event | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab |
|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/30 | 1/28 |
| DysphagiaGastrointestinal disorders | 0/30 | 1/28 |
| Urinary tract infectionInfections and infestations | 1/30 | 1/28 |
| GoutMetabolism and nutrition disorders | 0/30 | 1/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/30 | 1/28 |
| DizzinessNervous system disorders | 0/30 | 1/28 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/30 | 1/28 |
| DermatitisSkin and subcutaneous tissue disorders | 0/30 | 1/28 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/30 | 1/28 |
| Injection site reactionGeneral disorders | 1/30 | 0/28 |
Safety population included all randomized participants who received at least 1 dose of study medication. Participants in this group were included in the treatment group that they received, regardless of their randomized treatment.
| Age, Continuous(years) | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab | Total |
|---|---|---|---|
| Mean | 58.4 ± 11.16 | 62.0 ± 9.36 | 60.1 ± 10.40 |
| Sex: Female, Male(Participants) | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab | Total |
|---|---|---|---|
| Female | 15 | 21 | 36 |
| Male | 15 | 7 | 22 |
| Race/Ethnicity, Customized(Participants) | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab | Total |
|---|---|---|---|
| Black or African American | 2 | 4 | 6 |
| White | 28 | 24 | 52 |
| Baseline Low-Density Lipoprotein Cholesterol (L-DLC) Values(milligrams per deciliter (mg/dL)) | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab | Total |
|---|---|---|---|
| Mean | 104.12 ± 32.121 | 102.09 ± 28.982 | 103.14 ± 30.395 |
| Baseline Total Cholesterol (TC) and Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Values(mg/dL) | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab | Total |
|---|---|---|---|
| TC | 190.33 ± 39.387 | 186.20 ± 38.343 | 188.34 ± 38.601 |
| non-HDL-C | 132.95 ± 36.599 | 129.68 ± 36.301 | 131.37 ± 36.172 |
| Baseline Apolipoprotein B (apoB) Values(mg/dL) | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab | Total |
|---|---|---|---|
| Mean | 87.9 ± 23.80 | 87.5 ± 27.13 | 87.7 ± 25.29 |
| Baseline High-Sensitivity C-Reactive Protein (hs-CRP) Values(milligrams per Liter) | Placebo Plus Evolocumab | Bempedoic Acid Plus Evolocumab | Total |
|---|---|---|---|
| Median | 2.090 (1.120 to 4.690) | 3.125 (1.270 to 4.590) | 2.340 (1.170 to 4.640) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Jan 2018, 9 months.
Results were first posted in Apr 2020, 2 years 2 months after primary completion. A results delay was requested in Apr 2018.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 9 months is close to that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid